Expanded Access Program of Nasal Foralumab Enrolls 4 SPMS Patients
A group of four patients have entered a special program where theyāll gain access to foralumab nasal spray, an experimental therapy thatās being tested for non-active secondary progressive multiple sclerosis (SPMS). This is the first group of four who entered Tiziana Life Sciencesā intermediate-size expanded access program.